MedDataX Logo

Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample

NCT ID: NCT00568867

Last Updated: 2011-04-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-09-30

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate markers of immune response in human tumor samples.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms

NCT01390597

Lymphoma
COMPLETED

Identification of Key Blood Molecular Markers for Immunotherapy

NCT00507702

Squamous Cell Carcinoma Adenocarcinoma Neoplasms
TERMINATED

Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202

NCT01503619

Lung Cancer
COMPLETED

Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

NCT00899405

Lung Cancer
RECRUITING

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

NCT00349830

Carcinomas (Including Squamous Cell and Adenocarcinoma) Neoplasms
RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cancer immunotherapy has been shown to be effective in isolated instances, but ineffective in most patients. The reason for this inconsistency, and the conditions necessary for successful immunotherapy, are not well understood. Our studies in animal tumor models indicate that the effectiveness of IL-12-based immunotherapy depends upon the presence of a preexisting immune response to the tumor. The presence of T cell infiltrates and IFN-gamma expression in tumor indicate such an immune response. We therefore plan to evaluate the existing immune response in human tumor samples in an effort to identify those patients most likely to respond to therapy with IL-12.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria:Any adult patient with a tumor who is scheduled to undergo surgery to either remove or biopsy the tumor.

Exclusion Criteria

Exclusion Criteria:Patients without tumor and pediatric patients (children) will be excluded.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Stanford University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stanford University School of Medicine

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeffrey A. Norton

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stanford University School of Medicine

Stanford, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

97310

Identifier Type: OTHER

Identifier Source: secondary_id

VAR0018

Identifier Type: OTHER

Identifier Source: secondary_id

SU-11072007-830

Identifier Type: -

Identifier Source: org_study_id

NCT00507624

Identifier Type: -

Identifier Source: nct_alias

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
NCT02682667 RECRUITING
Molecular Analysis of Thoracic Malignancies
NCT01385722 ENROLLING_BY_INVITATION
A Research Pilot Study in Healthy Volunteers to Evaluate Biomarkers for Novel Anticancer Treatments
NCT00586417 TERMINATED NA
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 RECRUITING
Microscopy Imaging of Whole-mount Stained Human Tissues
NCT05689112 RECRUITING
Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherapeutics
NCT06630273 NOT_YET_RECRUITING
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
NCT00899496 COMPLETED
Immunobiology of Cancer
NCT00767533 TERMINATED
Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma
NCT00004153 COMPLETED NA
A Multicenter Cancer Biospecimen Collection Study
NCT04510129 RECRUITING
A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer
NCT05338060 ACTIVE_NOT_RECRUITING
Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells
NCT00020072 COMPLETED NA
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
NCT00904514 TERMINATED
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
NCT05600933 ENROLLING_BY_INVITATION
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors
NCT05683353 ACTIVE_NOT_RECRUITING
Study of Tissue and Blood Samples From Patients With High-Grade Glioma
NCT01004887 COMPLETED
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
NCT00568490 RECRUITING
In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients
NCT06827639 NOT_YET_RECRUITING
Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures
NCT05869994 WITHDRAWN
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
NCT00897481 UNKNOWN
Real-time Monitoring of Concentration and Size Variations of Circulating Plasma Free DNA to Predict Early Response to Immunotherapies in Patients With Different Types of Cancer.
NCT05083494 UNKNOWN
Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer
NCT00899860 TERMINATED
Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496
NCT00898963 COMPLETED
Immune Biomarker Study for Head and Neck Cancer
NCT05375266 RECRUITING
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
NCT03662204 COMPLETED